Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients (COMBAT/KEYNOTE-202) (COMBAT)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02826486 |
|
Recruitment Status :
Recruiting
First Posted : July 11, 2016
Last Update Posted : January 3, 2020
|
Sponsor:
BioLineRx, Ltd.
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
BioLineRx, Ltd.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | December 2021 |
| Estimated Study Completion Date : | December 2021 |